Beranda › Kanker Paru › California › Orange
Uji klinis Kanker Paru di Orange, CA
14 studi untuk Kanker Paru mencari peserta di lokasi sekitar Orange (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Menerima pesertaFase 3
- University of California, Irvine Health, Orange
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Menerima pesertaFase 3
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 4002), Orange
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- UC IRVINE Health, Orange
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Menerima pesertaFase 2/3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)
Menerima peserta
- Primary Care & Internal Medicine Services, Orange
- UCI Chao Family Comprehensive Cancer Center, Orange
- UCI Health SeniorHealth Center -Pavillion 4, Orange
- dan 1 lainnya
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- University of California Irvine, Orange
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Menerima pesertaFase 3
- Providence St. Joseph Hospital, Orange
Patient-Derived Xenografts to Reduce Cancer Health Disparities
Menerima pesertaStudi observasional
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Menerima pesertaFase 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Menerima pesertaFase 1/2
- UC Irvine/Chao Family Comprehensive Cancer Center, Orange
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Menerima pesertaFase 2
- University of California, Irvine Medical Center, Orange
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
Menerima pesertaFase 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Orange
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
Menerima peserta
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
Uji klinis Kanker Paru di kota lain
- Houston, TX78 studi
- Boston, MA62 studi
- New York City, NY60 studi
- Los Angeles, CA45 studi
- Washington, DC41 studi
- Arlington, VA41 studi
- Chicago, IL41 studi
- Nashville, TN40 studi
- Baltimore, MD40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
Studi lain di Orange
- Kanker Paru Non-Sel Kecil25 studi
- Kanker Metastatik20 studi
- Kanker Kolorektal16 studi
- Kanker Ovarium16 studi
- Kanker Pankreas15 studi
- Kanker Payudara14 studi
- Kanker Prostat14 studi
- Kanker Hati (Karsinoma Hepatoseluler)14 studi
- Melanoma14 studi
- Leukemia Mieloid Akut13 studi
- Kanker (semua jenis)13 studi
- Kanker Lambung13 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.